Denali Therapeutics Statistics
Total Valuation
DNLI has a market cap or net worth of $2.17 billion. The enterprise value is $1.26 billion.
Important Dates
The last earnings date was Monday, November 3, 2025, after market close.
| Earnings Date | Nov 3, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
DNLI has 146.42 million shares outstanding. The number of shares has increased by 14.84% in one year.
| Current Share Class | 146.42M |
| Shares Outstanding | 146.42M |
| Shares Change (YoY) | +14.84% |
| Shares Change (QoQ) | +0.13% |
| Owned by Insiders (%) | 4.79% |
| Owned by Institutions (%) | 94.39% |
| Float | 132.25M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.12 |
| P/TBV Ratio | 2.13 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.27, with a Debt / Equity ratio of 0.05.
| Current Ratio | 10.27 |
| Quick Ratio | 9.89 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -313.87 |
Financial Efficiency
Return on equity (ROE) is -39.69% and return on invested capital (ROIC) is -26.56%.
| Return on Equity (ROE) | -39.69% |
| Return on Assets (ROA) | -24.99% |
| Return on Invested Capital (ROIC) | -26.56% |
| Return on Capital Employed (ROCE) | -49.63% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.14M |
| Employee Count | 422 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, DNLI has paid $68,000 in taxes.
| Income Tax | 68,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -45.98% in the last 52 weeks. The beta is 1.13, so DNLI's price volatility has been higher than the market average.
| Beta (5Y) | 1.13 |
| 52-Week Price Change | -45.98% |
| 50-Day Moving Average | 15.11 |
| 200-Day Moving Average | 15.52 |
| Relative Strength Index (RSI) | 41.44 |
| Average Volume (20 Days) | 1,475,712 |
Short Selling Information
The latest short interest is 14.53 million, so 9.92% of the outstanding shares have been sold short.
| Short Interest | 14.53M |
| Short Previous Month | 14.15M |
| Short % of Shares Out | 9.92% |
| Short % of Float | 10.98% |
| Short Ratio (days to cover) | 6.94 |
Income Statement
| Revenue | n/a |
| Gross Profit | -396.06M |
| Operating Income | -533.58M |
| Pretax Income | -478.97M |
| Net Income | -479.03M |
| EBITDA | -529.42M |
| EBIT | -533.58M |
| Earnings Per Share (EPS) | -$2.81 |
Full Income Statement Balance Sheet
The company has $898.95 million in cash and $47.97 million in debt, giving a net cash position of $929.44 million or $6.35 per share.
| Cash & Cash Equivalents | 898.95M |
| Total Debt | 47.97M |
| Net Cash | 929.44M |
| Net Cash Per Share | $6.35 |
| Equity (Book Value) | 1.03B |
| Book Value Per Share | 7.05 |
| Working Capital | 843.65M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$349.62 million and capital expenditures -$18.33 million, giving a free cash flow of -$367.95 million.
| Operating Cash Flow | -349.62M |
| Capital Expenditures | -18.33M |
| Free Cash Flow | -367.95M |
| FCF Per Share | -$2.51 |
Full Cash Flow Statement Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
DNLI does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -14.84% |
| Shareholder Yield | -14.84% |
| Earnings Yield | -21.93% |
| FCF Yield | -16.84% |
Dividend Details Analyst Forecast
The average price target for DNLI is $32.64, which is 119.80% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $32.64 |
| Price Target Difference | 119.80% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 13 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | -32.47% |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |